Efficacy of mycophenolate on lung disease and autoimmunity in children with immunodeficiency

Pediatr Pulmonol. 2017 Oct;52(10):E73-E76. doi: 10.1002/ppul.23757. Epub 2017 Jul 3.

Abstract

The autoimmune manifestations of primary immunodeficiencies, such as autoimmune lymphoproliferative syndrome (ALPS) and common variable immunodeficiency (CVID), often constitute a great therapeutic challenge and have a significant impact on patients' morbidity and mortality. The most common autoimmune presentations are autoimmune cytopenias, but organ-related autoimmunity is also frequently observed. From a pulmonology perspective, granulomatous/lymphocytic interstitial lung disease (GLILD) is a severe immunological complication which significantly worsens the clinical outcome of these patients and for which there are currently few guidelines or protocols for treatment. We present three cases where the use of Mycophenolate in the context of autoimmune cytopenias proved beneficial also on the lung disease.

Keywords: ALPS; CVID; GLILD; interstitial lung disease; mycophenolate.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Autoimmune Diseases / drug therapy*
  • Autoimmunity / drug effects
  • Child, Preschool
  • Female
  • Humans
  • Immunologic Deficiency Syndromes / drug therapy*
  • Immunosuppressive Agents / therapeutic use*
  • Lung Diseases / drug therapy*
  • Male
  • Mycophenolic Acid / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid